Reckitt Benckiser Group Plc with ticker (LON:RKT) now has a potential upside of 6.4% according to Berenberg Bank.
RKT.L
Berenberg Bank set a target price of 5,177 GBX for the company, which when compared to the Reckitt Benckiser Group Plc share price of 4,865 GBX at opening today (25/11/2024) indicates a potential upside of 6.4%. Trading has ranged between 4,034 (52 week low) and 5,886 (52 week high) with an average of 1,751,367 shares exchanging hands daily. The market capitalisation at the time of writing is £41,995,210,000.
Reckitt Benckiser Group PLC (Reckitt) is a United Kingdom-based global consumer goods company. The Company’s operating segments comprise the Hygiene, Health, and Nutrition business. The Hygiene portfolio works to eliminate dirt, germs, pests, and odors with products such as Lysol, Finish, Air Wick, Harpic and Mortein. The Company’s Health portfolio offers various solutions that provide pain relief, protection, hygiene, and personal care to households across the world, through brands like Dettol, Durex, Gaviscon, Nurofen, Mucinex, Strepsils and Veet. The Nutrition business includes its infant and child nutrition, its adult nutrition and its range of vitamins, minerals, and supplements (VMS). Brands under Nutrition business include Enfa, Enfamil, Nutramigen, Airborne, Move Free and Neuriva. The Company’s brands also include Dettol, Lysol, Harpic, Finish, Durex, Mucinex, Enfamil and Move Free and more.
Reckitt Benckiser Group Plc 6.4% potential upside indicated by Berenberg Bank
- Written by: Charlotte Edwards
Latest Company News
Reckitt has appointed Deborah Waterhouse and Gavin Patterson to its Board as non-executive directors, effective from 1 July 2026.
Reckitt will host its latest “Focus On” investor seminar, highlighting how its digital and R&D teams use proprietary data, predictive science and generative AI to accelerate innovation and productivity. The event begins at 15:00 BST and will be led by Chief R&D Officer Angela Naef, alongside senior finance, technology and AI leaders.
Reckitt reported Q1 2026 like-for-like net revenue growth of 0.6% for the group and 1.3% for Core Reckitt, with strong emerging markets performance partly offset by weak seasonal OTC demand, softer Europe categories and disruption in the Middle East.
Reckitt Benckiser Group will hold its latest 'Reckitt Focus On' investor seminar, with today's session centred on Emerging Markets.
Reckitt Benckiser delivered a 7% rise in like-for-like group revenue for Q3 2025, supported by 6.7% growth in Core Reckitt and strong momentum in Emerging Markets.
Reckitt Benckiser delivered a strong H1 2025, with Core Reckitt like‑for‑like net revenues up 4.2% and Emerging Markets growth of 12.8%. Adjusted operating profit margin improved by 110 bps to 24.6%, supporting a 5% rise in the interim dividend and an upgrade to full‑year LFL net revenue guidance above 4% for Core Reckitt.
